Why is Caribou considered a likely reverse merger candidate now?

BioPharma Dive reported that Caribou, a struggling cell therapy developer, is exploring strategic alternatives, a setup that often makes the public listing itself part of the value. In biotech, that can attract reverse merger interest from private companies seeking market access without a traditional IPO.